首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal KITLG Antibody

  • 中文名: KITLG抗体
  • 别    名: SF; MGF; SCF; SLF; DCUA; FPH2; FPHH; KL-1; Kitl; SHEP7; DFNA69
货号: IPD32239
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/200 - 1/1000 Human,Mouse,Rat
ICC 1/200 - 1/1000 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

参考文献

以下是3篇关于KITLG(干细胞因子,SCF)抗体的代表性文献摘要:

1. **《Therapeutic targeting of KITLG/KIT signaling in metastatic melanoma》**

- 作者:Huang et al.

- 摘要:研究开发了一种靶向KITLG的人源化单克隆抗体,通过阻断KITLG与受体KIT的结合,抑制黑色素瘤细胞的迁移和转移。动物实验显示该抗体能显著减少肿瘤肺转移,提示其在晚期黑色素瘤治疗中的潜力。

2. **《KITLG antibodies disrupt spermatogonial stem cell niche in murine testes》**

- 作者:Zhang R, et al.

- 摘要:利用特异性抗KITLG抗体阻断小鼠睾丸微环境中的SCF信号,发现精原干细胞自我更新能力受损,揭示了KITLG在生殖干细胞维持中的关键作用,为男性不育机制研究提供依据。

3. **《Neutralizing anti-KITLG antibody attenuates allergic airway inflammation via mast cell inhibition》**

- 作者:Suzuki M, et al.

- 摘要:通过构建抗KITLG中和抗体,证实其能抑制肥大细胞活化及组胺释放,显著缓解小鼠哮喘模型的呼吸道高反应性,提出靶向KITLG可作为过敏性疾病的新型免疫调节策略。

背景信息

The KIT ligand (KITLG), also known as stem cell factor (SCF), is a critical cytokine that binds to the c-KIT receptor tyrosine kinase, regulating cellular processes like hematopoiesis, gametogenesis, melanogenesis, and mast cell development. KITLG exists in transmembrane and soluble forms, mediating paracrine or juxtacrine signaling. Dysregulation of the KITLG/c-KIT pathway is implicated in cancers (e.g., gastrointestinal stromal tumors, melanoma) and disorders like piebaldism. KITLG-targeting antibodies are therapeutic tools designed to modulate this pathway. Neutralizing antibodies can block KITLG-c-KIT interactions, inhibiting downstream pro-survival and proliferative signals in malignancies. Conversely, agonist antibodies may mimic KITLG to stimulate stem cell expansion or tissue repair. Diagnostic antibodies are also used to quantify KITLG expression in research or clinical settings. Recent advances include humanized antibodies to reduce immunogenicity and bispecific formats for enhanced targeting. Challenges include balancing efficacy with potential side effects, as c-KIT is expressed in multiple tissues. Ongoing research focuses on optimizing antibody specificity and exploring combination therapies to improve outcomes in cancer and regenerative medicine.

客户数据及评论

折叠内容

大包装询价

×